CM
CERO

Crestline Management’s CERo Therapeutics CERO Stock Holding History

Crestline Management’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-13
Closed -$251K – 272
2022
Q2 		$251K Buy
+13
New +$260K 0.03% 192

Other funds holding CERO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return

Crestline Management's CERO Position: Q3 2022 in Review

Crestline Management sold out of CERo Therapeutics (CERO) in Q3 2022, closing a stake of 13 shares — an estimated $251K sold.

Crestline Management first reported a position in CERO in Q2 2022 and held it in 1 quarter. The position peaked at $251K in Q2 2022. 65 funds tracked by Wall St. Rank hold CERO as of Q3 2022.

  • Crestline Management reported no remaining CERo Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Crestline Management sold 13 CERo Therapeutics shares in Q3 2022, an estimated $251K.
  • Crestline Management first reported a position in CERo Therapeutics in Q2 2022 and held it in 1 quarter.
  • Crestline Management's CERo Therapeutics position peaked at $251K in Q2 2022.
  • 65 funds tracked by Wall St. Rank held CERo Therapeutics as of Q3 2022.

Based on Crestline Management's 13F filing for Q3 2022, filed 14 Nov 2022.